| Farhat Kokan, MD | |
|
7920 Old Cedar Ave S, Bloomington, MN 55425 | |
| (952) 428-1800 | |
| Not Available |
| Full Name | Farhat Kokan |
|---|---|
| Gender | Female |
| Speciality | Allergy/immunology |
| Experience | 41 Years |
| Location | 7920 Old Cedar Ave S, Bloomington, Minnesota |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1932200557 | NPI | - | NPPES |
| 32470000 | Medicaid | WI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207K00000X | Allergy & Immunology | 38460 (Wisconsin) | Secondary |
| 207K00000X | Allergy & Immunology | 64687 (Minnesota) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Allina Health System | 4587573613 | 3071 |
News Archive
A powerful new cancer drug discovery database has been launched to speed up the process of bringing drugs from 'bench to bedside'.
Latest insights into immunity to HIV could help to develop a vaccine to build antibodies' defences against the disease, a University of Melbourne, Australia study has found.
Patients with non-small cell lung cancer in whom treatment with gefitinib is ineffective often have limited options, but results of a new study suggest that retreating patients with the same drug could have a beneficial effect.
GeNeuro SA, a pioneer of new therapies for neurology and autoimmune disorders, announced today that it has initiated its planned Phase IIb study "CHANGE-MS" (Clinical trial assessing the HERV-W Env ANtagonist GNbAC1 for Efficacy in Multiple Sclerosis) with its lead antibody GNbAC1 in Relapsing-Remitting Multiple Sclerosis (RRMS).
Impaired global longitudinal strain of the right ventricle predicts adverse outcomes in patients with pulmonary arterial hypertension, say investigators.
› Verified 8 days ago
| Entity Name | Allina Health System |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1295272342 PECOS PAC ID: 4587573613 Enrollment ID: O20040319000460 |
News Archive
A powerful new cancer drug discovery database has been launched to speed up the process of bringing drugs from 'bench to bedside'.
Latest insights into immunity to HIV could help to develop a vaccine to build antibodies' defences against the disease, a University of Melbourne, Australia study has found.
Patients with non-small cell lung cancer in whom treatment with gefitinib is ineffective often have limited options, but results of a new study suggest that retreating patients with the same drug could have a beneficial effect.
GeNeuro SA, a pioneer of new therapies for neurology and autoimmune disorders, announced today that it has initiated its planned Phase IIb study "CHANGE-MS" (Clinical trial assessing the HERV-W Env ANtagonist GNbAC1 for Efficacy in Multiple Sclerosis) with its lead antibody GNbAC1 in Relapsing-Remitting Multiple Sclerosis (RRMS).
Impaired global longitudinal strain of the right ventricle predicts adverse outcomes in patients with pulmonary arterial hypertension, say investigators.
› Verified 8 days ago
| Entity Name | Allina Health System |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1457657249 PECOS PAC ID: 4587573613 Enrollment ID: O20221213001713 |
News Archive
A powerful new cancer drug discovery database has been launched to speed up the process of bringing drugs from 'bench to bedside'.
Latest insights into immunity to HIV could help to develop a vaccine to build antibodies' defences against the disease, a University of Melbourne, Australia study has found.
Patients with non-small cell lung cancer in whom treatment with gefitinib is ineffective often have limited options, but results of a new study suggest that retreating patients with the same drug could have a beneficial effect.
GeNeuro SA, a pioneer of new therapies for neurology and autoimmune disorders, announced today that it has initiated its planned Phase IIb study "CHANGE-MS" (Clinical trial assessing the HERV-W Env ANtagonist GNbAC1 for Efficacy in Multiple Sclerosis) with its lead antibody GNbAC1 in Relapsing-Remitting Multiple Sclerosis (RRMS).
Impaired global longitudinal strain of the right ventricle predicts adverse outcomes in patients with pulmonary arterial hypertension, say investigators.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Farhat Kokan, MD 2925 Chicago Ave, Minneapolis, MN 55407-1321 Ph: (612) 262-5000 | Farhat Kokan, MD 7920 Old Cedar Ave S, Bloomington, MN 55425 Ph: (952) 428-1800 |
News Archive
A powerful new cancer drug discovery database has been launched to speed up the process of bringing drugs from 'bench to bedside'.
Latest insights into immunity to HIV could help to develop a vaccine to build antibodies' defences against the disease, a University of Melbourne, Australia study has found.
Patients with non-small cell lung cancer in whom treatment with gefitinib is ineffective often have limited options, but results of a new study suggest that retreating patients with the same drug could have a beneficial effect.
GeNeuro SA, a pioneer of new therapies for neurology and autoimmune disorders, announced today that it has initiated its planned Phase IIb study "CHANGE-MS" (Clinical trial assessing the HERV-W Env ANtagonist GNbAC1 for Efficacy in Multiple Sclerosis) with its lead antibody GNbAC1 in Relapsing-Remitting Multiple Sclerosis (RRMS).
Impaired global longitudinal strain of the right ventricle predicts adverse outcomes in patients with pulmonary arterial hypertension, say investigators.
› Verified 8 days ago